Anticancer Activity of RAS-GTP Inhibition in Cholangiocarcinoma
Rodrigo Entrialgo‐Cadierno(Universidad de Navarra), Inés López(Universidad de Navarra), Cristina Cueto‐Ureña(Universidad de Jaén), Yaiza Senent(Broad Institute), Ximo Pechuan-Jorge(Revolution Medicines (United States)), Mariano Ponz‐Sarvisé(Cold Spring Harbor Laboratory), Yingyun Wang(Revolution Medicines (United States)), Elizabeth Guruceaga(Universidad de Navarra), José M. Herranz(Vall d'Hebron Institute of Oncology), Mariana Yáñez-Bartolomé(Hebron University), Iker Feliu(Universidad de Navarra), Mallika Singh(Revolution Medicines (United States)), Ida Aronchik(Revolution Medicines (United States)), Teresa Macarulla(Vall d'Hebron Hospital Universitari), Jesús M. Bañales(University of the Basque Country), Irati Macaya(Foundation for Medical Research), Tian Tian(Shaanxi University of Chinese Medicine), Jingjing Jiang(Revolution Medicines (United States)), Jim Evans(Revolution Medicines (United States)), Javier Vaquero(Universidad de Salamanca), Rashi Raghulan(Revolution Medicines (United States)), Silvestre Vicent(Universidad de Navarra), Konstantina Morali(Universidad de Navarra)
Cited by 0
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.4k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
|Cell|2014|2.2k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423